Correction of Glycogen Storage Disease Type II by Systemic Delivery of an AAV2/8 Vector Containing a Muscle-Specific Promoter

被引：0
|
作者：
Sun, Baodong [1 ]
Li, Ping [2 ]
Talmage, Brown [3 ]
Andrew, Bird [1 ]
Yan, Zhen [2 ]
Koeberl, Dwight D. [1 ]
机构：
[1] Duke Univ, Med Ctr, Div Med Genet, Durham, NC USA
[2] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
[3] N Carolina State Univ, Coll Vet Med, Raleigh, NC USA
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.636
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
563
引用
收藏
页码：S217 / S217
页数：1
相关论文
共 40 条
  • [31] Nutritional management in adults with glycogen storage disease type Ia (GSDIa) enrolled in a phase 1/2 clinical trial of an AAV8-mediated liver-directed gene therapy
    Saavedra, H.
    Mount, M.
    Lipinski, S.
    Camba-Garea, M-J
    de Boer, F.
    Reineking, B.
    Rodriguez-Buritica, D. F.
    Riba-Wolman, R.
    Ahmad, A.
    Couce Pico, M. L.
    Derks, T. G.
    Mitchell, J.
    Weinstein, D. A.
    Lee, C.
    Valayannopoulos, V.
    Crombez, E.
    MOLECULAR GENETICS AND METABOLISM, 2022, 136 : S19 - S19
  • [32] Positive cohort 1 results from the phase 1/2, AAV8-mediated liver-directed gene therapy trial in glycogen storage disease type Ia (GSDIa)
    Derks, T. G.
    Martin-Hernandez, E.
    Ahmad, A.
    Rodriguez-Buritica, D.
    Mitchell, J.
    Lee, C.
    Poma, A.
    Crombez, E.
    Weinstein, D. A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A14 - A14
  • [33] AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Updated Phase 1/2 Clinical Trial Results
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Mari Luz Couce
    Derks, Terry G.
    Mitchell, John
    Riba-Wolman, Rebecca
    Mou, Jiani
    Poma, Allen
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR THERAPY, 2021, 29 (04) : 134 - 135
  • [34] AAV8-Mediated Liver-Directed Gene Therapy as a Potential Therapeutic Option in Adults with Glycogen Storage Disease Type Ia (GSDIa): Results from a Phase 1/2 Clinical Trial
    Weinstein, David A.
    Ahmad, Ayesha
    Rodriguez-Buritica, David F.
    Mitchell, John
    Derks, Terry G.
    Mou, Jiani
    Poma, Allen
    Crombez, Eric
    MOLECULAR THERAPY, 2020, 28 (04) : 558 - 558
  • [35] COHORT 1-4 RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF AN AAV8-MEDIATED LIVER-DIRECTED GENE THERAPY IN ADULTS WITH GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Mitchell, John
    Riba-Wolman, Rebecca
    Weinstein, David A.
    Lee, Connie
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 296 - 296
  • [36] Long-term, sustained efficacy and safety from a phase 1/2 clinical trial of an AAV8-mediated liver-directed gene therapy in adults with glycogen storage disease type Ia
    Pico, M. L. Couce
    Mitchell, J.
    Ahmad, A.
    Olmos, M.
    Derks, T. G.
    Riba-Wolman, R.
    Weinstein, D. A.
    Rodriguez-Buritica, D. F.
    Lee, C.
    Valayannopoulos, V.
    Crombez, E.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A28 - A28
  • [37] Sustained Efficacy and Safety at Week 52 and Up to Three Years in Adults with Glycogen Storage Disease Type iA (GSDIa): Results from a Phase 1/2 Clinical Trial of DTX401, an AAV8-mediated, Liver-Directed Gene Therapy
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Mitchell, John
    Weinstein, David A.
    Mitragotri, Deepali
    Valayannopoulos, Vassili
    Crombez, Eric
    MOLECULAR THERAPY, 2022, 30 (04) : 564 - 564
  • [38] Sustained efficacy and safety up to 3.5 years in adults with glycogen storage disease type Ia (GSDIa): longer-term results from a phase 1/2 clinical trial of DTX401, an AAV8-mediated, liver-directed gene therapy
    Mitchell, J.
    Derks, T. G.
    Riba-Wolman, R.
    Rodriguez-Buritica, D. F.
    Ahmad, A.
    Pico, M. L. Couce
    Weinstein, D. A.
    Mitragotri, D.
    Crombez, E.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A25 - A26
  • [39] Long-Term Efficacy and Safety in Adults with Glycogen Storage Disease Type IA (GSD IA) from a Phase 1/2 Clinical Trial and Long-Term Follow-Up Study of DTX401, an AAV8-Mediated, Liver-Directed Gene Therapy
    Mitchell, John J.
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David
    Ahmad, Ayesha
    Pico, Maria-Luz Couce
    Derks, Terry G.
    Weinstein, David A.
    Mitragotri, Deepali
    Collis, Richard
    Grimm, Andrew Alexander
    MOLECULAR THERAPY, 2024, 32 (04) : 78 - 79
  • [40] Efficacy and Safety at Week 52 and up to Four Years in Adults with Glycogen Storage Disease Type IA (GSDIa): Results from a Phase 1/2 Clinical Trial and Long-Term Follow-Up Study of DTX401, an AAV8-Mediated, Liver-Directed Gene Therapy
    Riba-Wolman, Rebecca
    Rodriguez-Buritica, David F.
    Ahmad, Ayesha
    Couce Pico, Maria-Luz
    Derks, Terry G.
    Mitchell, John
    Weinstein, David A.
    Mitragotri, Deepali
    Grimm, Andrew Alexander
    Crombez, Eric
    MOLECULAR THERAPY, 2023, 31 (04) : 2 - 3
1234